• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Technology Market
    Technology News
    Technology Stocks
    • Technology Market
    • Technology News
    • Technology Stocks

    Nuran Wireless Products Chosen for Clinical Trials

    Written by Morag Mcgreevey
    |
    Sep. 24, 2015 09:29AM PST

    Nuran Wireless (CSE:NUR) announces that its GMS SuperFemto and LiteCell solutions continue to be chosen for clinical trials across six countries and four continents.

    Nuran Wireless (CSE:NUR) announces that its GMS SuperFemto and LiteCell solutions continue to be chosen for clinical trials across six countries and four continents.
    According to the press release:

    NuRAN’s GSM LiteCell is a low-power (54W) and low operating expense (“OPEX”) GSM base station designed specifically for use in rural, low-density and lower average revenue per user (“ARPU”) urban areas.
    NuRAN’s GSM LiteCell has already been deployed in North and South America (including Mexico), Europe, Africa and Asia where it has given rural communities network coverage for the very first time.
    It is now being trialled by a number of additional operators and community organisations in South America and Africa providing voice coverage to villages in rural areas not currently covered by any kind of voice or data network as well as in urban areas where there are still opportunities to provide an affordable service to lower ARPU customers. Successful trials would convert into hundreds of units in the next coming months.
    NuRAN’s GSM-EDGE Superfemto can be deployed separately from GSM LiteCell to provide coverage in remote areas.  Applications include in-building coverage, offshore platforms and ships, private networks.
    According to GSMA Intelligence, 2G technology still accounts for 58.5 per cent of the world’s 7.11 billion mobile connections, compared to 32.5 per cent for 3G and 9 per cent for 4G. The analyst house expects 2G technology to maintain global market dominance.

    Click here to read the full press release from NuRAN.

    clinical trialseurope
    The Conversation (0)

    Go Deeper

    AI Powered
    Tech Outlook: Australia Edition

    Tech Outlook: Australia Edition

    Communication towers amid green hills at sunrise with blue transmission lines connecting them.

    Ericsson, Rogers Launch Canada’s First Underground 5G Network for Smart Mining

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES